Celularity Inc. - Class A

The momentum for this stock is not very good. Celularity Inc. - Class A is not very popular among insiders. Tradey thinks it is not wise to invest in Celularity Inc. - Class A.
Log in to see more information.

News

Celularity receives Nasdaq notice regarding late Form 10-Q filing
Celularity receives Nasdaq notice regarding late Form 10-Q filing

SeekingAlpha.com: All News Financial writer reports Celularity (CELU) receives notice from Nasdaq due to delayed Form 10-Q filings, risking compliance with listing requirements.\n more…

Celularity receives noncompliance notification from Nasdaq
Celularity receives noncompliance notification from Nasdaq

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

Vanguard Group Inc. Cuts Stake in Celularity Inc. (NASDAQ:CELU)
Vanguard Group Inc. Cuts Stake in Celularity Inc. (NASDAQ:CELU)

Ticker Report Vanguard Group Inc. lowered its position in Celularity Inc. (NASDAQ:CELU - Free Report) by 89.7% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities...\n more…

Head to Head Comparison: Celularity (NASDAQ:CELU) versus Dynavax Technologies (NASDAQ:DVAX)
Head to Head Comparison: Celularity (NASDAQ:CELU) versus Dynavax Technologies (NASDAQ:DVAX)

Zolmax Dynavax Technologies (NASDAQ:DVAX - Get Free Report) and Celularity (NASDAQ:CELU - Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two...\n more…

Celularity Board Member Marc Mazur Announces Resignation
Celularity Board Member Marc Mazur Announces Resignation

TipRanks Financial Blog Celularity (CELU) has shared an update. Marc Mazur, a key board member of Celularity, has announced his resignation, effective July 31, 2024. His departure is not t...\n more…

Celularity sees Q1 net sales of biomaterial product, biobanking $14.8M
Celularity sees Q1 net sales of biomaterial product, biobanking $14.8M

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…